Pharmacogenomics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027
The global pharmacogenomics market reached a value of US$ 6.6 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 11.3 Billion by 2027, exhibiting a CAGR of 9.3% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
Pharmacogenomics is the study of inherited variations in human genes in response to specific drugs. It utilizes the principles of pharmacology and genomics to develop effective and safe medications that are customized to the genetic makeup of an individual. It involves the use of various technologies, such as polymerase chain reaction (PCR), microarray, deoxyribonucleic acid (DNA) sequencing, mass spectrometry and electrophoresis. The genetic tests performed in pharmacogenomics aid in determining the susceptibility to certain diseases and efficacy of the newly developed drugs. Pharmacogenomics is also widely used in the treatment of various diseases, such as cardiovascular, Alzheimer's, cancer, human immunodeficiency virus and acquired immunodeficiency syndrome (HIV/AIDS) and asthma.
Pharmacogenomics Market Trends:
Significant growth in the pharmaceutical industry across the globe is one of the key factors creating a positive outlook for the market. Moreover, the increasing demand for precision medicines with enhanced drug safety is providing a thrust to the growth of the market. With the increasing prevalence of chronic lifestyle diseases, there is widespread adoption of targeted drug therapies with minimal side effects and improved efficacy. In line with this, pharmacogenomics is also extensively used for cancer treatments and anticipating the possible drug responses, resistance, efficacy and toxicity of the chemotherapeutic and targeted immune biologic agents, which is also contributing to the market growth. Additionally, various technological advancements, such as the development of pharmacogenomic biomarker labeling solutions, are acting as other growth-inducing factors. They aid in minimizing the risks of avoidable adverse drug reactions (ADRs) in the body and improve clinical outcomes. Other factors, including extensive research and development (R&D) activities, along with significant improvements in the healthcare infrastructure, are anticipated to drive the market toward growth.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global pharmacogenomics market, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on technology, application and end user.
Breakup by Technology:
Polymerase Chain Reaction
Microarray
DNA Sequencing
Mass Spectrometry
Electrophoresis
Others
Breakup by Application:
Oncology
Infectious Diseases
Cardiovascular Diseases
Neurological Diseases
Psychiatry
Pain Management
Others
Breakup by End User:
Hospitals and Clinics
Academic and Research Institutes
Breakup by Region:
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, AstraZeneca plc, Bayer AG, Becton Dickinson and Company, Bio-Rad Laboratories Inc., F. Hoffmann-La Roche AG, GlaxoSmithKline plc, Illumina Inc., Johnson & Johnson, Merck KGaA, Myriad Genetics Inc., Qiagen N.V. and Thermo Fisher Scientific Inc.
Key Questions Answered in This Report:
How has the global pharmacogenomics market performed so far and how will it perform in the coming years?
What has been the impact of COVID-19 on the global pharmacogenomics market?
What are the key regional markets?
What is the breakup of the market based on the technology?
What is the breakup of the market based on the application?
What is the breakup of the market based on the end user?
What are the various stages in the value chain of the industry?
What are the key driving factors and challenges in the industry?
What is the structure of the global pharmacogenomics market and who are the key players?
What is the degree of competition in the industry?
Pharmacogenomics is the study of inherited variations in human genes in response to specific drugs. It utilizes the principles of pharmacology and genomics to develop effective and safe medications that are customized to the genetic makeup of an individual. It involves the use of various technologies, such as polymerase chain reaction (PCR), microarray, deoxyribonucleic acid (DNA) sequencing, mass spectrometry and electrophoresis. The genetic tests performed in pharmacogenomics aid in determining the susceptibility to certain diseases and efficacy of the newly developed drugs. Pharmacogenomics is also widely used in the treatment of various diseases, such as cardiovascular, Alzheimer's, cancer, human immunodeficiency virus and acquired immunodeficiency syndrome (HIV/AIDS) and asthma.
Pharmacogenomics Market Trends:
Significant growth in the pharmaceutical industry across the globe is one of the key factors creating a positive outlook for the market. Moreover, the increasing demand for precision medicines with enhanced drug safety is providing a thrust to the growth of the market. With the increasing prevalence of chronic lifestyle diseases, there is widespread adoption of targeted drug therapies with minimal side effects and improved efficacy. In line with this, pharmacogenomics is also extensively used for cancer treatments and anticipating the possible drug responses, resistance, efficacy and toxicity of the chemotherapeutic and targeted immune biologic agents, which is also contributing to the market growth. Additionally, various technological advancements, such as the development of pharmacogenomic biomarker labeling solutions, are acting as other growth-inducing factors. They aid in minimizing the risks of avoidable adverse drug reactions (ADRs) in the body and improve clinical outcomes. Other factors, including extensive research and development (R&D) activities, along with significant improvements in the healthcare infrastructure, are anticipated to drive the market toward growth.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global pharmacogenomics market, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on technology, application and end user.
Breakup by Technology:
Polymerase Chain Reaction
Microarray
DNA Sequencing
Mass Spectrometry
Electrophoresis
Others
Breakup by Application:
Oncology
Infectious Diseases
Cardiovascular Diseases
Neurological Diseases
Psychiatry
Pain Management
Others
Breakup by End User:
Hospitals and Clinics
Academic and Research Institutes
Breakup by Region:
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, AstraZeneca plc, Bayer AG, Becton Dickinson and Company, Bio-Rad Laboratories Inc., F. Hoffmann-La Roche AG, GlaxoSmithKline plc, Illumina Inc., Johnson & Johnson, Merck KGaA, Myriad Genetics Inc., Qiagen N.V. and Thermo Fisher Scientific Inc.
Key Questions Answered in This Report:
How has the global pharmacogenomics market performed so far and how will it perform in the coming years?
What has been the impact of COVID-19 on the global pharmacogenomics market?
What are the key regional markets?
What is the breakup of the market based on the technology?
What is the breakup of the market based on the application?
What is the breakup of the market based on the end user?
What are the various stages in the value chain of the industry?
What are the key driving factors and challenges in the industry?
What is the structure of the global pharmacogenomics market and who are the key players?
What is the degree of competition in the industry?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 INTRODUCTION
4.1 Overview
4.2 Key Industry Trends
5 GLOBAL PHARMACOGENOMICS MARKET
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 MARKET BREAKUP BY TECHNOLOGY
6.1 Polymerase Chain Reaction
6.1.1 Market Trends
6.1.2 Market Forecast
6.2 Microarray
6.2.1 Market Trends
6.2.2 Market Forecast
6.3 DNA Sequencing
6.3.1 Market Trends
6.3.2 Market Forecast
6.4 Mass Spectrometry
6.4.1 Market Trends
6.4.2 Market Forecast
6.5 Electrophoresis
6.5.1 Market Trends
6.5.2 Market Forecast
6.6 Others
6.6.1 Market Trends
6.6.2 Market Forecast
7 MARKET BREAKUP BY APPLICATION
7.1 Oncology
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Infectious Diseases
7.2.1 Market Trends
7.2.2 Market Forecast
7.3 Cardiovascular Diseases
7.3.1 Market Trends
7.3.2 Market Forecast
7.4 Neurological Diseases
7.4.1 Market Trends
7.4.2 Market Forecast
7.5 Psychiatry
7.5.1 Market Trends
7.5.2 Market Forecast
7.6 Pain Management
7.6.1 Market Trends
7.6.2 Market Forecast
7.7 Others
7.7.1 Market Trends
7.7.2 Market Forecast
8 MARKET BREAKUP BY END USER
8.1 Hospitals and Clinics
8.1.1 Market Trends
8.1.2 Market Forecast
8.2 Academic and Research Institutes
8.2.1 Market Trends
8.2.2 Market Forecast
9 MARKET BREAKUP BY REGION
9.1 North America
9.1.1 United States
9.1.1.1 Market Trends
9.1.1.2 Market Forecast
9.1.2 Canada
9.1.2.1 Market Trends
9.1.2.2 Market Forecast
9.2 Asia-Pacific
9.2.1 China
9.2.1.1 Market Trends
9.2.1.2 Market Forecast
9.2.2 Japan
9.2.2.1 Market Trends
9.2.2.2 Market Forecast
9.2.3 India
9.2.3.1 Market Trends
9.2.3.2 Market Forecast
9.2.4 South Korea
9.2.4.1 Market Trends
9.2.4.2 Market Forecast
9.2.5 Australia
9.2.5.1 Market Trends
9.2.5.2 Market Forecast
9.2.6 Indonesia
9.2.6.1 Market Trends
9.2.6.2 Market Forecast
9.2.7 Others
9.2.7.1 Market Trends
9.2.7.2 Market Forecast
9.3 Europe
9.3.1 Germany
9.3.1.1 Market Trends
9.3.1.2 Market Forecast
9.3.2 France
9.3.2.1 Market Trends
9.3.2.2 Market Forecast
9.3.3 United Kingdom
9.3.3.1 Market Trends
9.3.3.2 Market Forecast
9.3.4 Italy
9.3.4.1 Market Trends
9.3.4.2 Market Forecast
9.3.5 Spain
9.3.5.1 Market Trends
9.3.5.2 Market Forecast
9.3.6 Russia
9.3.6.1 Market Trends
9.3.6.2 Market Forecast
9.3.7 Others
9.3.7.1 Market Trends
9.3.7.2 Market Forecast
9.4 Latin America
9.4.1 Brazil
9.4.1.1 Market Trends
9.4.1.2 Market Forecast
9.4.2 Mexico
9.4.2.1 Market Trends
9.4.2.2 Market Forecast
9.4.3 Others
9.4.3.1 Market Trends
9.4.3.2 Market Forecast
9.5 Middle East and Africa
9.5.1 Market Trends
9.5.2 Market Breakup by Country
9.5.3 Market Forecast
10 SWOT ANALYSIS
10.1 Overview
10.2 Strengths
10.3 Weaknesses
10.4 Opportunities
10.5 Threats
11 VALUE CHAIN ANALYSIS
12 PORTERS FIVE FORCES ANALYSIS
12.1 Overview
12.2 Bargaining Power of Buyers
12.3 Bargaining Power of Suppliers
12.4 Degree of Competition
12.5 Threat of New Entrants
12.6 Threat of Substitutes
13 PRICE ANALYSIS
14 COMPETITIVE LANDSCAPE
14.1 Market Structure
14.2 Key Players
14.3 Profiles of Key Players
14.3.1 Abbott Laboratories
14.3.1.1 Company Overview
14.3.1.2 Product Portfolio
14.3.1.3 Financials
14.3.1.4 SWOT Analysis
14.3.2 AstraZeneca plc
14.3.2.1 Company Overview
14.3.2.2 Product Portfolio
14.3.2.3 Financials
14.3.2.4 SWOT Analysis
14.3.3 Bayer AG
14.3.3.1 Company Overview
14.3.3.2 Product Portfolio
14.3.3.3 Financials
14.3.3.4 SWOT Analysis
14.3.4 Becton Dickinson and Company
14.3.4.1 Company Overview
14.3.4.2 Product Portfolio
14.3.4.3 Financials
14.3.4.4 SWOT Analysis
14.3.5 Bio-Rad Laboratories Inc.
14.3.5.1 Company Overview
14.3.5.2 Product Portfolio
14.3.5.3 Financials
14.3.5.4 SWOT Analysis
14.3.6 F. Hoffmann-La Roche AG
14.3.6.1 Company Overview
14.3.6.2 Product Portfolio
14.3.6.3 SWOT Analysis
14.3.7 GlaxoSmithKline plc
14.3.7.1 Company Overview
14.3.7.2 Product Portfolio
14.3.7.3 Financials
14.3.7.4 SWOT Analysis
14.3.8 Illumina Inc.
14.3.8.1 Company Overview
14.3.8.2 Product Portfolio
14.3.8.3 Financials
14.3.8.4 SWOT Analysis
14.3.9 Johnson & Johnson
14.3.9.1 Company Overview
14.3.9.2 Product Portfolio
14.3.9.3 Financials
14.3.9.4 SWOT Analysis
14.3.10 Merck KGaA
14.3.10.1 Company Overview
14.3.10.2 Product Portfolio
14.3.10.3 Financials
14.3.10.4 SWOT Analysis
14.3.11 Myriad Genetics Inc.
14.3.11.1 Company Overview
14.3.11.2 Product Portfolio
14.3.11.3 Financials
14.3.11.4 SWOT Analysis
14.3.12 Qiagen N.V.
14.3.12.1 Company Overview
14.3.12.2 Product Portfolio
14.3.12.3 Financials
14.3.12.4 SWOT Analysis
14.3.13 Thermo Fisher Scientific Inc
14.3.13.1 Company Overview
14.3.13.2 Product Portfolio
14.3.13.3 Financials
14.3.13.4 SWOT Analysis
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 INTRODUCTION
4.1 Overview
4.2 Key Industry Trends
5 GLOBAL PHARMACOGENOMICS MARKET
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 MARKET BREAKUP BY TECHNOLOGY
6.1 Polymerase Chain Reaction
6.1.1 Market Trends
6.1.2 Market Forecast
6.2 Microarray
6.2.1 Market Trends
6.2.2 Market Forecast
6.3 DNA Sequencing
6.3.1 Market Trends
6.3.2 Market Forecast
6.4 Mass Spectrometry
6.4.1 Market Trends
6.4.2 Market Forecast
6.5 Electrophoresis
6.5.1 Market Trends
6.5.2 Market Forecast
6.6 Others
6.6.1 Market Trends
6.6.2 Market Forecast
7 MARKET BREAKUP BY APPLICATION
7.1 Oncology
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Infectious Diseases
7.2.1 Market Trends
7.2.2 Market Forecast
7.3 Cardiovascular Diseases
7.3.1 Market Trends
7.3.2 Market Forecast
7.4 Neurological Diseases
7.4.1 Market Trends
7.4.2 Market Forecast
7.5 Psychiatry
7.5.1 Market Trends
7.5.2 Market Forecast
7.6 Pain Management
7.6.1 Market Trends
7.6.2 Market Forecast
7.7 Others
7.7.1 Market Trends
7.7.2 Market Forecast
8 MARKET BREAKUP BY END USER
8.1 Hospitals and Clinics
8.1.1 Market Trends
8.1.2 Market Forecast
8.2 Academic and Research Institutes
8.2.1 Market Trends
8.2.2 Market Forecast
9 MARKET BREAKUP BY REGION
9.1 North America
9.1.1 United States
9.1.1.1 Market Trends
9.1.1.2 Market Forecast
9.1.2 Canada
9.1.2.1 Market Trends
9.1.2.2 Market Forecast
9.2 Asia-Pacific
9.2.1 China
9.2.1.1 Market Trends
9.2.1.2 Market Forecast
9.2.2 Japan
9.2.2.1 Market Trends
9.2.2.2 Market Forecast
9.2.3 India
9.2.3.1 Market Trends
9.2.3.2 Market Forecast
9.2.4 South Korea
9.2.4.1 Market Trends
9.2.4.2 Market Forecast
9.2.5 Australia
9.2.5.1 Market Trends
9.2.5.2 Market Forecast
9.2.6 Indonesia
9.2.6.1 Market Trends
9.2.6.2 Market Forecast
9.2.7 Others
9.2.7.1 Market Trends
9.2.7.2 Market Forecast
9.3 Europe
9.3.1 Germany
9.3.1.1 Market Trends
9.3.1.2 Market Forecast
9.3.2 France
9.3.2.1 Market Trends
9.3.2.2 Market Forecast
9.3.3 United Kingdom
9.3.3.1 Market Trends
9.3.3.2 Market Forecast
9.3.4 Italy
9.3.4.1 Market Trends
9.3.4.2 Market Forecast
9.3.5 Spain
9.3.5.1 Market Trends
9.3.5.2 Market Forecast
9.3.6 Russia
9.3.6.1 Market Trends
9.3.6.2 Market Forecast
9.3.7 Others
9.3.7.1 Market Trends
9.3.7.2 Market Forecast
9.4 Latin America
9.4.1 Brazil
9.4.1.1 Market Trends
9.4.1.2 Market Forecast
9.4.2 Mexico
9.4.2.1 Market Trends
9.4.2.2 Market Forecast
9.4.3 Others
9.4.3.1 Market Trends
9.4.3.2 Market Forecast
9.5 Middle East and Africa
9.5.1 Market Trends
9.5.2 Market Breakup by Country
9.5.3 Market Forecast
10 SWOT ANALYSIS
10.1 Overview
10.2 Strengths
10.3 Weaknesses
10.4 Opportunities
10.5 Threats
11 VALUE CHAIN ANALYSIS
12 PORTERS FIVE FORCES ANALYSIS
12.1 Overview
12.2 Bargaining Power of Buyers
12.3 Bargaining Power of Suppliers
12.4 Degree of Competition
12.5 Threat of New Entrants
12.6 Threat of Substitutes
13 PRICE ANALYSIS
14 COMPETITIVE LANDSCAPE
14.1 Market Structure
14.2 Key Players
14.3 Profiles of Key Players
14.3.1 Abbott Laboratories
14.3.1.1 Company Overview
14.3.1.2 Product Portfolio
14.3.1.3 Financials
14.3.1.4 SWOT Analysis
14.3.2 AstraZeneca plc
14.3.2.1 Company Overview
14.3.2.2 Product Portfolio
14.3.2.3 Financials
14.3.2.4 SWOT Analysis
14.3.3 Bayer AG
14.3.3.1 Company Overview
14.3.3.2 Product Portfolio
14.3.3.3 Financials
14.3.3.4 SWOT Analysis
14.3.4 Becton Dickinson and Company
14.3.4.1 Company Overview
14.3.4.2 Product Portfolio
14.3.4.3 Financials
14.3.4.4 SWOT Analysis
14.3.5 Bio-Rad Laboratories Inc.
14.3.5.1 Company Overview
14.3.5.2 Product Portfolio
14.3.5.3 Financials
14.3.5.4 SWOT Analysis
14.3.6 F. Hoffmann-La Roche AG
14.3.6.1 Company Overview
14.3.6.2 Product Portfolio
14.3.6.3 SWOT Analysis
14.3.7 GlaxoSmithKline plc
14.3.7.1 Company Overview
14.3.7.2 Product Portfolio
14.3.7.3 Financials
14.3.7.4 SWOT Analysis
14.3.8 Illumina Inc.
14.3.8.1 Company Overview
14.3.8.2 Product Portfolio
14.3.8.3 Financials
14.3.8.4 SWOT Analysis
14.3.9 Johnson & Johnson
14.3.9.1 Company Overview
14.3.9.2 Product Portfolio
14.3.9.3 Financials
14.3.9.4 SWOT Analysis
14.3.10 Merck KGaA
14.3.10.1 Company Overview
14.3.10.2 Product Portfolio
14.3.10.3 Financials
14.3.10.4 SWOT Analysis
14.3.11 Myriad Genetics Inc.
14.3.11.1 Company Overview
14.3.11.2 Product Portfolio
14.3.11.3 Financials
14.3.11.4 SWOT Analysis
14.3.12 Qiagen N.V.
14.3.12.1 Company Overview
14.3.12.2 Product Portfolio
14.3.12.3 Financials
14.3.12.4 SWOT Analysis
14.3.13 Thermo Fisher Scientific Inc
14.3.13.1 Company Overview
14.3.13.2 Product Portfolio
14.3.13.3 Financials
14.3.13.4 SWOT Analysis
LIST OF TABLES
Table 1: Global: Pharmacogenomics Market: Key Industry Highlights, 2021 and 2027
Table 2: Global: Pharmacogenomics Market Forecast: Breakup by Technology (in Million US$), 2022-2027
Table 3: Global: Pharmacogenomics Market Forecast: Breakup by Application (in Million US$), 2022-2027
Table 4: Global: Pharmacogenomics Market Forecast: Breakup by End User (in Million US$), 2022-2027
Table 5: Global: Pharmacogenomics Market Forecast: Breakup by Region (in Million US$), 2022-2027
Table 6: Global: Pharmacogenomics Market: Competitive Structure
Table 7: Global: Pharmacogenomics Market: Key Players
Table 1: Global: Pharmacogenomics Market: Key Industry Highlights, 2021 and 2027
Table 2: Global: Pharmacogenomics Market Forecast: Breakup by Technology (in Million US$), 2022-2027
Table 3: Global: Pharmacogenomics Market Forecast: Breakup by Application (in Million US$), 2022-2027
Table 4: Global: Pharmacogenomics Market Forecast: Breakup by End User (in Million US$), 2022-2027
Table 5: Global: Pharmacogenomics Market Forecast: Breakup by Region (in Million US$), 2022-2027
Table 6: Global: Pharmacogenomics Market: Competitive Structure
Table 7: Global: Pharmacogenomics Market: Key Players
LIST OF FIGURES
Figure 1: Global: Pharmacogenomics Market: Major Drivers and Challenges
Figure 2: Global: Pharmacogenomics Market: Sales Value (in Billion US$), 2016-2021
Figure 3: Global: Pharmacogenomics Market Forecast: Sales Value (in Billion US$), 2022-2027
Figure 4: Global: Pharmacogenomics Market: Breakup by Technology (in %), 2021
Figure 5: Global: Pharmacogenomics Market: Breakup by Application (in %), 2021
Figure 6: Global: Pharmacogenomics Market: Breakup by End User (in %), 2021
Figure 7: Global: Pharmacogenomics Market: Breakup by Region (in %), 2021
Figure 8: Global: Pharmacogenomics (Polymerase Chain Reaction) Market: Sales Value (in Million US$), 2016 & 2021
Figure 9: Global: Pharmacogenomics (Polymerase Chain Reaction) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 10: Global: Pharmacogenomics (Microarray) Market: Sales Value (in Million US$), 2016 & 2021
Figure 11: Global: Pharmacogenomics (Microarray) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 12: Global: Pharmacogenomics (DNA Sequencing) Market: Sales Value (in Million US$), 2016 & 2021
Figure 13: Global: Pharmacogenomics (DNA Sequencing) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 14: Global: Pharmacogenomics (Mass Spectrometry) Market: Sales Value (in Million US$), 2016 & 2021
Figure 15: Global: Pharmacogenomics (Mass Spectrometry) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 16: Global: Pharmacogenomics (Electrophoresis) Market: Sales Value (in Million US$), 2016 & 2021
Figure 17: Global: Pharmacogenomics (Electrophoresis) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 18: Global: Pharmacogenomics (Other Technologies) Market: Sales Value (in Million US$), 2016 & 2021
Figure 19: Global: Pharmacogenomics (Other Technologies) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 20: Global: Pharmacogenomics (Oncology) Market: Sales Value (in Million US$), 2016 & 2021
Figure 21: Global: Pharmacogenomics (Oncology) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 22: Global: Pharmacogenomics (Infectious Diseases) Market: Sales Value (in Million US$), 2016 & 2021
Figure 23: Global: Pharmacogenomics (Infectious Diseases) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 24: Global: Pharmacogenomics (Cardiovascular Diseases) Market: Sales Value (in Million US$), 2016 & 2021
Figure 25: Global: Pharmacogenomics (Cardiovascular Diseases) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 26: Global: Pharmacogenomics (Neurological Diseases) Market: Sales Value (in Million US$), 2016 & 2021
Figure 27: Global: Pharmacogenomics (Neurological Diseases) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 28: Global: Pharmacogenomics (Psychiatry) Market: Sales Value (in Million US$), 2016 & 2021
Figure 29: Global: Pharmacogenomics (Psychiatry) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 30: Global: Pharmacogenomics (Pain Management) Market: Sales Value (in Million US$), 2016 & 2021
Figure 31: Global: Pharmacogenomics (Pain Management) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 32: Global: Pharmacogenomics (Other Applications) Market: Sales Value (in Million US$), 2016 & 2021
Figure 33: Global: Pharmacogenomics (Other Applications) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 34: Global: Pharmacogenomics (Hospitals and Clinics) Market: Sales Value (in Million US$), 2016 & 2021
Figure 35: Global: Pharmacogenomics (Hospitals and Clinics) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 36: Global: Pharmacogenomics (Academic and Research Institutes) Market: Sales Value (in Million US$), 2016 & 2021
Figure 37: Global: Pharmacogenomics (Academic and Research Institutes) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 38: North America: Pharmacogenomics Market: Sales Value (in Million US$), 2016 & 2021
Figure 39: North America: Pharmacogenomics Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 40: United States: Pharmacogenomics Market: Sales Value (in Million US$), 2016 & 2021
Figure 41: United States: Pharmacogenomics Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 42: Canada: Pharmacogenomics Market: Sales Value (in Million US$), 2016 & 2021
Figure 43: Canada: Pharmacogenomics Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 44: Asia-Pacific: Pharmacogenomics Market: Sales Value (in Million US$), 2016 & 2021
Figure 45: Asia-Pacific: Pharmacogenomics Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 46: China: Pharmacogenomics Market: Sales Value (in Million US$), 2016 & 2021
Figure 47: China: Pharmacogenomics Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 48: Japan: Pharmacogenomics Market: Sales Value (in Million US$), 2016 & 2021
Figure 49: Japan: Pharmacogenomics Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 50: India: Pharmacogenomics Market: Sales Value (in Million US$), 2016 & 2021
Figure 51: India: Pharmacogenomics Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 52: South Korea: Pharmacogenomics Market: Sales Value (in Million US$), 2016 & 2021
Figure 53: South Korea: Pharmacogenomics Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 54: Australia: Pharmacogenomics Market: Sales Value (in Million US$), 2016 & 2021
Figure 55: Australia: Pharmacogenomics Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 56: Indonesia: Pharmacogenomics Market: Sales Value (in Million US$), 2016 & 2021
Figure 57: Indonesia: Pharmacogenomics Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 58: Others: Pharmacogenomics Market: Sales Value (in Million US$), 2016 & 2021
Figure 59: Others: Pharmacogenomics Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 60: Europe: Pharmacogenomics Market: Sales Value (in Million US$), 2016 & 2021
Figure 61: Europe: Pharmacogenomics Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 62: Germany: Pharmacogenomics Market: Sales Value (in Million US$), 2016 & 2021
Figure 63: Germany: Pharmacogenomics Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 64: France: Pharmacogenomics Market: Sales Value (in Million US$), 2016 & 2021
Figure 65: France: Pharmacogenomics Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 66: United Kingdom: Pharmacogenomics Market: Sales Value (in Million US$), 2016 & 2021
Figure 67: United Kingdom: Pharmacogenomics Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 68: Italy: Pharmacogenomics Market: Sales Value (in Million US$), 2016 & 2021
Figure 69: Italy: Pharmacogenomics Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 70: Spain: Pharmacogenomics Market: Sales Value (in Million US$), 2016 & 2021
Figure 71: Spain: Pharmacogenomics Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 72: Russia: Pharmacogenomics Market: Sales Value (in Million US$), 2016 & 2021
Figure 73: Russia: Pharmacogenomics Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 74: Others: Pharmacogenomics Market: Sales Value (in Million US$), 2016 & 2021
Figure 75: Others: Pharmacogenomics Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 76: Latin America: Pharmacogenomics Market: Sales Value (in Million US$), 2016 & 2021
Figure 77: Latin America: Pharmacogenomics Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 78: Brazil: Pharmacogenomics Market: Sales Value (in Million US$), 2016 & 2021
Figure 79: Brazil: Pharmacogenomics Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 80: Mexico: Pharmacogenomics Market: Sales Value (in Million US$), 2016 & 2021
Figure 81: Mexico: Pharmacogenomics Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 82: Others: Pharmacogenomics Market: Sales Value (in Million US$), 2016 & 2021
Figure 83: Others: Pharmacogenomics Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 84: Middle East and Africa: Pharmacogenomics Market: Sales Value (in Million US$), 2016 & 2021
Figure 85: Middle East and Africa: Pharmacogenomics Market: Breakup by Country (in %), 2021
Figure 86: Middle East and Africa: Pharmacogenomics Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 87: Global: Pharmacogenomics Industry: SWOT Analysis
Figure 88: Global: Pharmacogenomics Industry: Value Chain Analysis
Figure 89: Global: Pharmacogenomics Industry: Porter's Five Forces Analysis
Figure 1: Global: Pharmacogenomics Market: Major Drivers and Challenges
Figure 2: Global: Pharmacogenomics Market: Sales Value (in Billion US$), 2016-2021
Figure 3: Global: Pharmacogenomics Market Forecast: Sales Value (in Billion US$), 2022-2027
Figure 4: Global: Pharmacogenomics Market: Breakup by Technology (in %), 2021
Figure 5: Global: Pharmacogenomics Market: Breakup by Application (in %), 2021
Figure 6: Global: Pharmacogenomics Market: Breakup by End User (in %), 2021
Figure 7: Global: Pharmacogenomics Market: Breakup by Region (in %), 2021
Figure 8: Global: Pharmacogenomics (Polymerase Chain Reaction) Market: Sales Value (in Million US$), 2016 & 2021
Figure 9: Global: Pharmacogenomics (Polymerase Chain Reaction) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 10: Global: Pharmacogenomics (Microarray) Market: Sales Value (in Million US$), 2016 & 2021
Figure 11: Global: Pharmacogenomics (Microarray) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 12: Global: Pharmacogenomics (DNA Sequencing) Market: Sales Value (in Million US$), 2016 & 2021
Figure 13: Global: Pharmacogenomics (DNA Sequencing) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 14: Global: Pharmacogenomics (Mass Spectrometry) Market: Sales Value (in Million US$), 2016 & 2021
Figure 15: Global: Pharmacogenomics (Mass Spectrometry) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 16: Global: Pharmacogenomics (Electrophoresis) Market: Sales Value (in Million US$), 2016 & 2021
Figure 17: Global: Pharmacogenomics (Electrophoresis) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 18: Global: Pharmacogenomics (Other Technologies) Market: Sales Value (in Million US$), 2016 & 2021
Figure 19: Global: Pharmacogenomics (Other Technologies) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 20: Global: Pharmacogenomics (Oncology) Market: Sales Value (in Million US$), 2016 & 2021
Figure 21: Global: Pharmacogenomics (Oncology) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 22: Global: Pharmacogenomics (Infectious Diseases) Market: Sales Value (in Million US$), 2016 & 2021
Figure 23: Global: Pharmacogenomics (Infectious Diseases) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 24: Global: Pharmacogenomics (Cardiovascular Diseases) Market: Sales Value (in Million US$), 2016 & 2021
Figure 25: Global: Pharmacogenomics (Cardiovascular Diseases) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 26: Global: Pharmacogenomics (Neurological Diseases) Market: Sales Value (in Million US$), 2016 & 2021
Figure 27: Global: Pharmacogenomics (Neurological Diseases) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 28: Global: Pharmacogenomics (Psychiatry) Market: Sales Value (in Million US$), 2016 & 2021
Figure 29: Global: Pharmacogenomics (Psychiatry) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 30: Global: Pharmacogenomics (Pain Management) Market: Sales Value (in Million US$), 2016 & 2021
Figure 31: Global: Pharmacogenomics (Pain Management) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 32: Global: Pharmacogenomics (Other Applications) Market: Sales Value (in Million US$), 2016 & 2021
Figure 33: Global: Pharmacogenomics (Other Applications) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 34: Global: Pharmacogenomics (Hospitals and Clinics) Market: Sales Value (in Million US$), 2016 & 2021
Figure 35: Global: Pharmacogenomics (Hospitals and Clinics) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 36: Global: Pharmacogenomics (Academic and Research Institutes) Market: Sales Value (in Million US$), 2016 & 2021
Figure 37: Global: Pharmacogenomics (Academic and Research Institutes) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 38: North America: Pharmacogenomics Market: Sales Value (in Million US$), 2016 & 2021
Figure 39: North America: Pharmacogenomics Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 40: United States: Pharmacogenomics Market: Sales Value (in Million US$), 2016 & 2021
Figure 41: United States: Pharmacogenomics Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 42: Canada: Pharmacogenomics Market: Sales Value (in Million US$), 2016 & 2021
Figure 43: Canada: Pharmacogenomics Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 44: Asia-Pacific: Pharmacogenomics Market: Sales Value (in Million US$), 2016 & 2021
Figure 45: Asia-Pacific: Pharmacogenomics Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 46: China: Pharmacogenomics Market: Sales Value (in Million US$), 2016 & 2021
Figure 47: China: Pharmacogenomics Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 48: Japan: Pharmacogenomics Market: Sales Value (in Million US$), 2016 & 2021
Figure 49: Japan: Pharmacogenomics Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 50: India: Pharmacogenomics Market: Sales Value (in Million US$), 2016 & 2021
Figure 51: India: Pharmacogenomics Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 52: South Korea: Pharmacogenomics Market: Sales Value (in Million US$), 2016 & 2021
Figure 53: South Korea: Pharmacogenomics Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 54: Australia: Pharmacogenomics Market: Sales Value (in Million US$), 2016 & 2021
Figure 55: Australia: Pharmacogenomics Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 56: Indonesia: Pharmacogenomics Market: Sales Value (in Million US$), 2016 & 2021
Figure 57: Indonesia: Pharmacogenomics Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 58: Others: Pharmacogenomics Market: Sales Value (in Million US$), 2016 & 2021
Figure 59: Others: Pharmacogenomics Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 60: Europe: Pharmacogenomics Market: Sales Value (in Million US$), 2016 & 2021
Figure 61: Europe: Pharmacogenomics Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 62: Germany: Pharmacogenomics Market: Sales Value (in Million US$), 2016 & 2021
Figure 63: Germany: Pharmacogenomics Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 64: France: Pharmacogenomics Market: Sales Value (in Million US$), 2016 & 2021
Figure 65: France: Pharmacogenomics Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 66: United Kingdom: Pharmacogenomics Market: Sales Value (in Million US$), 2016 & 2021
Figure 67: United Kingdom: Pharmacogenomics Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 68: Italy: Pharmacogenomics Market: Sales Value (in Million US$), 2016 & 2021
Figure 69: Italy: Pharmacogenomics Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 70: Spain: Pharmacogenomics Market: Sales Value (in Million US$), 2016 & 2021
Figure 71: Spain: Pharmacogenomics Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 72: Russia: Pharmacogenomics Market: Sales Value (in Million US$), 2016 & 2021
Figure 73: Russia: Pharmacogenomics Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 74: Others: Pharmacogenomics Market: Sales Value (in Million US$), 2016 & 2021
Figure 75: Others: Pharmacogenomics Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 76: Latin America: Pharmacogenomics Market: Sales Value (in Million US$), 2016 & 2021
Figure 77: Latin America: Pharmacogenomics Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 78: Brazil: Pharmacogenomics Market: Sales Value (in Million US$), 2016 & 2021
Figure 79: Brazil: Pharmacogenomics Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 80: Mexico: Pharmacogenomics Market: Sales Value (in Million US$), 2016 & 2021
Figure 81: Mexico: Pharmacogenomics Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 82: Others: Pharmacogenomics Market: Sales Value (in Million US$), 2016 & 2021
Figure 83: Others: Pharmacogenomics Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 84: Middle East and Africa: Pharmacogenomics Market: Sales Value (in Million US$), 2016 & 2021
Figure 85: Middle East and Africa: Pharmacogenomics Market: Breakup by Country (in %), 2021
Figure 86: Middle East and Africa: Pharmacogenomics Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 87: Global: Pharmacogenomics Industry: SWOT Analysis
Figure 88: Global: Pharmacogenomics Industry: Value Chain Analysis
Figure 89: Global: Pharmacogenomics Industry: Porter's Five Forces Analysis
